Targets › PDE4B
17 programs from 14 companies in 64 trials: 32 Phase 2, 15 Phase 1, 11 Phase 3, 6 Phase 4; Immunology, Psychiatry, Other; next expected readout Nov 2026.
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. (UniProt, Q07343)
Open in Phaseline: the race on PDE4B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Integrative Skin Science and Research | Roflumilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 4 | ITCH | Aug 2027 |
| Massachusetts General Hospital | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 4 | PHP Ia | Apr 2030 |
| Cairo University | Crisaborole Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Vitiligo | Nov 2026 |
| Ganzhou Hemay Pharmaceutical | Hemay005 Phosphodiesterase 4 (PDE4) inhibitor | PDE4A, PDE4B, PDE4C, PDE4D | Phase 3 | Behçet's Disease; Moderate to Severe Ulcerative Colitis; Psoriasis | Dec 2026 |
| Amgen | Apremilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Plaque Psoriasis; Active Juvenile Psoriatic Arthritis; Behçet Disease; Behçet's Disease … | Mar 2028 |
| Arcutis Biotherapeutics | Roflumilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Atopic Dermatitis; Chronic Plaque Psoriasis; Depressive Disorder, Major; Fragile X Syndrome … | Apr 2028 |
| Merck & Co. (MSD) | Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 3 | Pulmonary Disease, Chronic Obstructive | Apr 2029 |
| Vanderbilt University Medical Center | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Pseudohypoparathyroidism | Dec 2026 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis Bronchiectasis | Mar 2027 |
| Beni-Suef University | Aminophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Acute Calculous Anuria; Pediatric Urolithiasis; Renal Stones | Mar 2027 |
| MediciNova | Ibudilast (MN-166) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Amyotrophic Lateral Sclerosis | Apr 2027 |
| Medical College of Wisconsin | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 1 | Acute Kidney Injury | May 2027 |
| National Institute of Mental Health (NIMH) | 18F-PF-06445974 PDE4B radiotracer for PET imaging | PDE4B | Phase 1 | Alcohol Use Disorder | Feb 2028 |
| National Institute of Mental Health (NIMH) | [18F]PF-06445974 PDE4B radioligand for PET imaging | PDE4B | Phase 1 | Depression | Oct 2028 |
| National Institute of Mental Health (NIMH) | [11C]ZTP-1 PDE4B imaging tracer (11C-labeled) | PDE4B | Phase 1 | Healthy | Mar 2029 |
| National Institute of Mental Health (NIMH) | 18F-PF974 PDE4B radiotracer for PET imaging | PDE4B | Phase 1 | Alzheimer s Disease | Apr 2029 |
Alcohol Use Disorder (7) Behçet's Disease (2) Pseudohypoparathyroidism (2) Acute Kidney Injury (2) Head and Neck Squamous Cell Carcinoma (2) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Hidradenitis Suppurativa (HS) (2) Plaque Psoriasis (1) Active Juvenile Psoriatic Arthritis (1) Behçet Disease (1) Recurrent Aphtous Stomatitis (1)
small molecule (17)
National Institute of Mental Health (NIMH) (4) Amgen (1) MediciNova (1) Beni-Suef University (1) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1) Ganzhou Hemay Pharmaceutical (1) Vanderbilt University Medical Center (1) Cairo University (1) University of Pennsylvania (1) Merck & Co. (MSD) (1) Medical College of Wisconsin (1) Massachusetts General Hospital (1) Arcutis Biotherapeutics (1) Integrative Skin Science and Research (1)
PDE4A (13) PDE4D (13) PDE4C (13) PDE3A (8) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.